Safety of an intravenous second generation contrast agent in patients with severe left ventricular dysfunction [1]

Heart

Volumn 84, Issue 6, 2000, Pages 634-635

  Soman, P ^a   Lahiri, A ^a   Senior, R ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; PLACEBO; SONOVUE;

CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTRAST ECHOCARDIOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART RIGHT ATRIUM PRESSURE; HUMAN; LETTER; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE;

CONTRAST MEDIA; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; SULFUR HEXAFLUORIDE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0033656616     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction. New insights using myocardial contrast echocardiography
2. Hibernating myocardium
3. Intravenous injection of Albunex microspheres causes thromboxane mediated pulmonary hypertension in pigs, but not in monkeys or rabbits
4. BR1: A new ultrasonographic contrast agent based on sulphur hexafluoride